SAR and QSAR in Environmental Research is a leading journal published by Taylor & Francis Ltd, focusing on the integration of Structure-Activity Relationships (SAR) and Quantitative Structure-Activity Relationships (QSAR) within the realm of environmental science. Since its inception in 1993, the journal has been a pivotal platform for disseminating innovative research that bridges the gap between chemistry and environmental sustainability, ranking in the Q3 quartile for Bioengineering, Drug Discovery, and miscellaneous Medicine categories as of 2023. Featuring a compelling collection of peer-reviewed articles, it caters to academic and professional audiences seeking to enhance their understanding of molecular interactions and their implications for environmental health. Although the journal does not currently offer Open Access options, its rigorous editorial standards ensure high-quality, impactful publications that are crucial for advancing methodologies in pharmacology, toxicology, and bioengineering. With an ISSN of 1062-936X and an E-ISSN of 1029-046X, SAR and QSAR in Environmental Research continues to serve as an essential resource for researchers, academics, and practitioners dedicated to innovative approaches in environmental research.

MEDICINAL RESEARCH REVIEWS, published by Wiley, is a leading journal in the fields of Drug Discovery, Molecular Medicine, and Pharmacology. With an impressive impact factor and esteemed standing in its category quartiles (Q1 in all three fields), this journal serves as a vital platform for the dissemination of cutting-edge research and reviews that drive innovation in therapeutic development and molecular health sciences. Since its inception in 1981, MEDICINAL RESEARCH REVIEWS has garnered a robust readership within the scientific community, underscored by its high rankings in Scopus – where it ranks #3 in Pharmacology and #2 in Drug Discovery, placing it within the top echelons of academic influence. Researchers, professionals, and students alike benefit from its rich content and comprehensive approaches to tackling complex medicinal challenges, making it an essential resource for those invested in advancing the frontiers of biomedical research.

MOLECULAR DIVERSITY, published by Springer, stands as a pivotal platform within the fields of chemistry, biology, and pharmacology since its inception in 1995. This esteemed journal aims to foster interdisciplinary research and innovation, particularly in areas such as catalysis, drug discovery, inorganic and organic chemistry, and molecular biology. With a diverse scope that reflects contemporary scientific challenges, it has been recognized for its significant contributions, boasting commendable Scopus rankings and an impact factor that underscores its relevance in critical fields. Although not an open access journal, MOLECULAR DIVERSITY continues to influence and engage researchers, professionals, and students alike by providing a forum for high-quality peer-reviewed articles and cutting-edge research findings. As it converges years of scientific dynamism from 1995 to 2024, this journal remains vital for those advancing the frontiers of molecular science and engineering.

MINI-REVIEWS IN MEDICINAL CHEMISTRY is a distinguished journal published by Bentham Science Publishers, dedicated to the cutting-edge field of medicinal chemistry. With an ISSN of 1389-5575 and an E-ISSN of 1875-5607, this journal serves as an essential platform for researchers and professionals to disseminate concise yet comprehensive reviews that capture the latest advancements and trends in drug discovery, cancer research, pharmacology, and molecular medicine. Operating since 2001, it has consistently maintained a relevant presence in academia with its impressive rank metrics, including a Q2 category in Drug Discovery and Pharmacology in 2023, highlighting its significance in the scientific community. The journal is recognized for its rigorous peer-review process and provides an invaluable resource for students and researchers seeking insights into the rapidly evolving landscape of medicinal chemistry. With a commitment to excellence and innovation, MINI-REVIEWS IN MEDICINAL CHEMISTRY continues to foster knowledge exchange and inspire future breakthroughs in healthcare and therapeutic advancements.

BIOORGANIC & MEDICINAL CHEMISTRY, published by Pergamon-Elsevier Science Ltd, is a prominent journal in the fields of biochemical research and drug discovery, with an ISSN of 0968-0896 and an E-ISSN of 1464-3391. Established in 1993, it has garnered respect and recognition, evidenced by its categorization in various quartile ranks across 2023, including Q2 in Clinical Biochemistry and Pharmaceutical Science. It holds significant Scopus rankings, placing it in the 75th percentile in Pharmaceutical Science and 74th percentile in Organic Chemistry, highlighting its influential contributions to ongoing research and developments. This journal provides a platform for disseminating advancements in bioorganic and medicinal chemistry, focusing on innovative methodologies, therapeutic advancements, and molecular pharmacology. Although it does not follow an open-access model, it remains a key resource for researchers, professionals, and students aiming to stay at the forefront of scientific discovery in the UK and beyond. The journal’s commitment to enhancing knowledge within the biomedical community makes it an essential read for those passionate about this dynamic field.

COMPUTATIONAL BIOLOGY AND CHEMISTRY is a distinguished academic journal published by Elsevier Science Ltd, focusing on the dynamic intersection of computational biology, biochemistry, and chemistry. With an ISSN of 1476-9271 and an E-ISSN of 1476-928X, this journal is committed to disseminating high-quality research that employs computational techniques to solve complex biological and chemical problems. As of 2023, the journal holds a substantial impact factor reflecting its significance and rigorous peer-review process, categorized in the Q2 quartile for both Computational Mathematics and Organic Chemistry, alongside Q3 classifications in Biochemistry and Structural Biology. With a continuous publication history spanning from 2003 to 2024, it serves as a critical resource for researchers, professionals, and students alike. The journal offers various open access options, ensuring that vital research findings are accessible to a global audience, further enhancing collaboration across disciplines. Engage with cutting-edge studies and contribute to the evolving landscape of computational methodologies in the life sciences through this esteemed publication.

Drug Research, published by GEORG THIEME VERLAG KG, is a pivotal journal housed in the vibrant realm of pharmacology and drug discovery. With a commitment to advancing the understanding of medicinal substances, this journal serves as an essential resource for researchers, professionals, and students dedicated to the field. The journal boasts an ISSN of 2194-9379 and an E-ISSN of 2194-9387, reflecting its dual commitment to print and digital accessibility. Despite its status as a Q3 journal in both Drug Discovery and Miscellaneous Medicine categories as of 2023, it continues to offer valuable insights with a focus on the latest innovations, methodologies, and findings in drug research. Based in Germany, Drug Research promotes scholarly communication and collaboration within the scientific community, ensuring that its contributions remain impactful in shaping future therapeutic discoveries. The journal is indexed in relevant databases, enhancing its visibility and reach, thus fostering a robust academic dialogue.

The Journal of Computational Biophysics and Chemistry, published by World Scientific Publishing Co. Pte Ltd, is a distinguished platform dedicated to advancing the fields of biophysics and computational chemistry. With an ISSN of 2737-4165 and an E-ISSN of 2737-4173, this journal has garnered attention since its inception, earning a Q3 ranking in Computational Theory and Mathematics and Q4 rankings in both Computer Science Applications and Physical and Theoretical Chemistry as of 2023. The scope of the journal encompasses innovative research that integrates computational techniques with biochemical applications, making it essential reading for researchers, professionals, and students alike. With open access options available, the journal ensures that cutting-edge findings are easily accessible to a global audience, thereby fostering collaboration and innovation in the scientific community. Based in Singapore, the journal aims to converge ideas and methodologies from 2021 to 2024, paving the way for transformative insights in computational methods. Join a community at the forefront of research and applications that bridge disciplines through rigorous scholarship and pioneering discoveries.

JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH is a prestigious publication in the field of natural products, focusing on valuable research spanning analytical chemistry, pharmacology, and complementary medicine. Published by Taylor & Francis Ltd in the United Kingdom, this journal has established itself as a key resource for academics and professionals seeking to explore advancements in drug discovery and organic chemistry. With a converged publication timeline from 1998 to 2024, the journal boasts several commendable category quartiles as of 2023, reflecting its robust standing in the research community: Q2 in Complementary and Alternative Medicine, Q3 in multiple domains including Analytical Chemistry and Organic Chemistry, and Q4 in Molecular Medicine. Although it currently does not offer open access, the journal remains a valuable compendium for empirical research and innovative studies in areas such as pharmacology and medicinal chemistry. Researchers, professionals, and students alike will find the JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH to be an essential platform for sharing groundbreaking findings and fostering collaborations that lead to significant advancements in science and health.

DRUG DEVELOPMENT RESEARCH is a premier interdisciplinary journal published by Wiley, focusing on the latest advancements in drug discovery, pharmacology, and toxicology. With an ISSN of 0272-4391 and an E-ISSN of 1098-2299, this esteemed publication has been a cornerstone in the field since its inception in 1981 and continues to provide cutting-edge research until 2024. Its rigorous peer-review process and strategic placement in Q2 of the Drug Discovery category, as well as ranking #60 out of 157 in Scopus, underscore the journal's relevance and influence, boasting a respectable 62nd percentile ranking. While the journal does not currently offer open access, it remains a vital resource for researchers, professionals, and students seeking to expand their knowledge on the processes of drug development, identifying new therapeutic targets, and assessing the efficacy and safety of novel compounds. Situated in Hoboken, NJ, this journal stands at the forefront of pharmaceutical innovation, making significant contributions to the advancement of medical science.